<DOC>
	<DOCNO>NCT01044017</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , cross-over study evaluate glucose concentration glycemic parameter efficacy , safety tolerability pharmacokinetics single oral dos RO4998452 patient diabetes mellitus type 2 . On 3 treatment day week apart , patient receive orally one 2 dose level RO4998452 placebo . Anticipated time study treatment 3 week . Target sample size &lt; 50 .</brief_summary>
	<brief_title>A Study Single Doses RO4998452 Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Adult patient , 1875 year age Type 2 diabetes mellitus , diagnose least 3 month screen Treatment diet exercise BMI 27 40 kg/m2 Type 1 diabetes History ketoacidosis , hyperosmolar coma , lactic acidosis Renal disease renal dysfunction Evidence significant diabetic complication Currently within 3 month prior screen treat oral injectable antidiabetic agent ( exception : insulin injection emergency situation ) History antidiabetic triple therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>